Browsing Tag
Bipolar I disorder
3 posts
FDA clears Bysanti and suddenly Vanda Pharmaceuticals Inc has no margin for execution failure
FDA approval of Bysanti sends Vanda Pharmaceuticals Inc stock higher. Read why execution now matters more than hype in schizophrenia and bipolar markets.
UZEDY wins FDA nod for Bipolar I maintenance therapy, boosting Teva and Medincell’s psychiatric drug portfolio
FDA expands UZEDY approval to Bipolar I maintenance therapy — explore how Teva and Medincell’s long-acting risperidone strategy is reshaping psychiatric care.
Can Alembic Pharmaceuticals challenge Latuda with its FDA-approved Lurasidone Hydrochloride Tablets?
Find out how Alembic Pharmaceuticals’ FDA approval for Lurasidone Hydrochloride Tablets positions the drugmaker in the $3.7B bipolar depression market.